Tourmaline Bio Agrees to Merge With Talaris Therapeutics
New York – June 22, 2023 – Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement. Lawyers Bill Sorabella, Brandon Fenn and Matthew Silverman led the Cooley team advising Tourmaline.
The proposed transaction values Tourmaline Bio at approximately $230 million, and includes approximately $75 million from the concurrent private placement with leading life sciences investors.
The combined company will operate as Tourmaline Bio.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.